Aquinnah Pharmaceuticals is using newly discovered brain pathology to design innovative therapies to slow the progression of ALS and other neurodegenerative diseases.
Aquinnah was founded by Ben Wolozin, who has led the discovery of disease-linked protein aggregation in neurologic diseases and is chairman of the National Institutes of Health Cellular and Molecular Biology Neurodegeneration Study Section.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/aquinnah-pharmaceuticals” connections=”true” suffix=””]
Aquinnah is using the groundbreaking new biology of stress granules to design new therapies for ALS and have identified drug leads designed to prevent and reverse the pathological stress granules in affected patients.
June 2018, Aquinnah is awarded $3.4 million from the National Institute of Neurological Disorders and Stroke (NINDS).
Aug 2017, two pharmaceutical companies, Pfizer Inc. and AbbVie Inc. have invested $10 million in Aquinnahs work to treat ALS (Amyotrophic Lateral Sclerosis), Alzheimers disease and other neurodegenerative diseases.
In Dec 2015, Aquinnah received $5 Mn investment from Takeda Pharmaceuticals to advance its new therapies for ALS. Previously company has also received two grants totaling $500,000 from the ALS Association to support its preclinical research.
Recover your password.
A password will be e-mailed to you.